<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Daiichi Sankyo Company, Limited — News on 6ix</title>
<link>https://6ix.com/company/daiichi-sankyo-company-limited</link>
<description>Latest news and press releases for Daiichi Sankyo Company, Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 20 Feb 2026 00:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/daiichi-sankyo-company-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d621d4beedb30cb6fc2e4e.webp</url>
<title>Daiichi Sankyo Company, Limited</title>
<link>https://6ix.com/company/daiichi-sankyo-company-limited</link>
</image>
<item>
<title>Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D</title>
<link>https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-appoints-john-tsai-md-as-global-head-of-randd</link>
<guid isPermaLink="true">https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-appoints-john-tsai-md-as-global-head-of-randd</guid>
<pubDate>Fri, 20 Feb 2026 00:00:00 GMT</pubDate>
<description>TOKYO & BASKING RIDGE, N.J., February 20, 2026--Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&D, effective April 1, 2026.</description>
</item>
<item>
<title>Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe</title>
<link>https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-appoints-new-leadership-at-the-daiichi-sankyo-translational-research-center-europe</link>
<guid isPermaLink="true">https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-appoints-new-leadership-at-the-daiichi-sankyo-translational-research-center-europe</guid>
<pubDate>Thu, 22 Jan 2026 06:30:00 GMT</pubDate>
<description>TOKYO & MUNICH, January 22, 2026--Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe.</description>
</item>
<item>
<title>Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS</title>
<link>https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-showcases-strength-of-industry-leading-adc-portfolio-with-latest-research-updates-from-five-landmark-breast-cancer-trials-at-sabcs</link>
<guid isPermaLink="true">https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-showcases-strength-of-industry-leading-adc-portfolio-with-latest-research-updates-from-five-landmark-breast-cancer-trials-at-sabcs</guid>
<pubDate>Mon, 08 Dec 2025 12:00:00 GMT</pubDate>
<description>TOKYO & BASKING RIDGE, N.J., December 08, 2025--Daiichi Sankyo (TSE: 4568) will present new breast cancer clinical research across its DXd antibody drug conjugate (ADC) portfolio from more than 30 abstracts at the 2025 San Antonio Breast Cancer Symposium (#SABCS25), which include four rapid fire mini-oral sessions and other presentations from five landmark trials of ENHERTU® (trastuzumab deruxtecan) and DATROWAY® (datopotamab deruxtecan) across a broad spectrum of breast cancer.</description>
</item>
<item>
<title>Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen</title>
<link>https://6ix.com/company/daiichi-sankyo-company-limited/news/federal-circuit-court-of-appeals-vacates-infringement-judgment-and-damages-award-in-dispute-between-daiichi-sankyo-and-seagen</link>
<guid isPermaLink="true">https://6ix.com/company/daiichi-sankyo-company-limited/news/federal-circuit-court-of-appeals-vacates-infringement-judgment-and-damages-award-in-dispute-between-daiichi-sankyo-and-seagen</guid>
<pubDate>Wed, 03 Dec 2025 12:00:00 GMT</pubDate>
<description>TOKYO & BASKING RIDGE, N.J., December 03, 2025--On December 2, the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) reversed a decision from the U.S. District Court for the Eastern District of Texas that found Seagen Inc’s U.S. Patent No. 10,808,039 (the ’039 patent) not invalid (the Texas decision). In view of the reversal, the Federal Circuit vacated the Texas court’s related infringement judgment and damages award against Daiichi Sankyo.</description>
</item>
<item>
<title>Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO</title>
<link>https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-continues-to-transform-standards-of-care-for-patients-with-three-landmark-breast-cancer-trials-and-additional-data-across-industry-leading-adc-portfolio-at-esmo</link>
<guid isPermaLink="true">https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-continues-to-transform-standards-of-care-for-patients-with-three-landmark-breast-cancer-trials-and-additional-data-across-industry-leading-adc-portfolio-at-esmo</guid>
<pubDate>Mon, 13 Oct 2025 11:00:00 GMT</pubDate>
<description>TOKYO & BASKING RIDGE, N.J., October 13, 2025--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio with four late-breaking presentations from more than 20 abstracts at the 2025 European Society for Medical Oncology (#ESMO25) Congress.</description>
</item>
<item>
<title>Daiichi Sankyo Establishes Third Research Institute in San Diego</title>
<link>https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-establishes-third-research-institute-in-san-diego</link>
<guid isPermaLink="true">https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-establishes-third-research-institute-in-san-diego</guid>
<pubDate>Thu, 02 Oct 2025 11:00:00 GMT</pubDate>
<description>TOKYO & BASKING RIDGE, N.J., October 02, 2025--Daiichi Sankyo (TSE: 4568) has established Daiichi Sankyo Research Institute in San Diego, representing the third research institute established outside of the company’s flagship research center in Japan since the opening of locations in Boston and Munich in 2024.</description>
</item>
<item>
<title>Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C</title>
<link>https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-announces-the-development-of-a-fixed-triple-combination-lipid-lowering-tablet-to-address-persistent-gaps-in-the-management-of-elevated-ldl-c</link>
<guid isPermaLink="true">https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-announces-the-development-of-a-fixed-triple-combination-lipid-lowering-tablet-to-address-persistent-gaps-in-the-management-of-elevated-ldl-c</guid>
<pubDate>Sat, 30 Aug 2025 16:00:00 GMT</pubDate>
<description>MUNICH, Germany, August 30, 2025--Daiichi Sankyo Europe is pleased to announce the development of a fixed-triple oral combination lipid-lowering tablet of bempedoic acid, ezetimibe, and different doses of a statin, with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.i ii</description>
</item>
<item>
<title>Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C</title>
<link>https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-announces-the-initiation-of-the-development-of-oral-triple-combination-lipid-lowering-tablets-to-support-the-management-of-ldl-c</link>
<guid isPermaLink="true">https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-announces-the-initiation-of-the-development-of-oral-triple-combination-lipid-lowering-tablets-to-support-the-management-of-ldl-c</guid>
<pubDate>Sat, 30 Aug 2025 16:00:00 GMT</pubDate>
<description>MUNICH, Germany, August 30, 2025--Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal o</description>
</item>
<item>
<title>Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer at WCLC</title>
<link>https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-presents-new-data-in-small-cell-lung-cancer-and-updates-across-adc-portfolio-highlighting-progress-in-creating-new-standards-of-care-for-patients-with-lung-cancer-at-wclc</link>
<guid isPermaLink="true">https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-presents-new-data-in-small-cell-lung-cancer-and-updates-across-adc-portfolio-highlighting-progress-in-creating-new-standards-of-care-for-patients-with-lung-cancer-at-wclc</guid>
<pubDate>Thu, 14 Aug 2025 12:00:00 GMT</pubDate>
<description>TOKYO & BASKING RIDGE, N.J., August 14, 2025--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in lung cancer at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC25).</description>
</item>
<item>
<title>Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO</title>
<link>https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-continues-to-transform-treatment-landscape-for-patients-with-cancer-with-practice-changing-data-at-asco</link>
<guid isPermaLink="true">https://6ix.com/company/daiichi-sankyo-company-limited/news/daiichi-sankyo-continues-to-transform-treatment-landscape-for-patients-with-cancer-with-practice-changing-data-at-asco</guid>
<pubDate>Thu, 22 May 2025 21:00:00 GMT</pubDate>
<description>BASKING RIDGE, N.J., May 22, 2025--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology Scientific Program (#ASCO25).</description>
</item>
</channel>
</rss>